{"parse":{"title":"Access to medicines","pageid":53143403,"revid":851144623,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Access to medicines</b> refers to the reasonable ability for people to get needed <a href=\"/wiki/Medicines\" class=\"mw-redirect\" title=\"Medicines\">medicines</a> required to achieve <a href=\"/wiki/Health\" title=\"Health\">health</a>.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup> Such access is deemed to be part of the <a href=\"/wiki/Right_to_health\" title=\"Right to health\">right to health</a> as supported by <a href=\"/wiki/International_law\" title=\"International law\">international law</a> since 1946.<sup id=\"cite_ref-WHO2017_2-0\" class=\"reference\"><a href=\"#cite_note-WHO2017-2\">&#91;2&#93;</a></sup>\n</p><p>The <a href=\"/wiki/World_Health_Organization\" title=\"World Health Organization\">World Health Organization</a> states that <a href=\"/wiki/Essential_medicines\" title=\"Essential medicines\">essential medicines</a> should be available, of good quality, and accessible.<sup id=\"cite_ref-WHO2017_2-1\" class=\"reference\"><a href=\"#cite_note-WHO2017-2\">&#91;2&#93;</a></sup> Reasonable access to medicines can be in conflict with <a href=\"/wiki/Intellectual_property\" title=\"Intellectual property\">intellectual property</a> and <a href=\"/wiki/Free_markets\" class=\"mw-redirect\" title=\"Free markets\">free markets</a>.<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup> In the <a href=\"/wiki/Developing_world\" class=\"mw-redirect\" title=\"Developing world\">developing world</a> people may not get treatment for conditions like <a href=\"/wiki/HIV/AIDS\" title=\"HIV/AIDS\">HIV/AIDS</a>.<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Hindrances_to_access\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Hindrances to access</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#Patent_protection_and_exclusivity\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">Patent protection and exclusivity</span></a></li>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#Data_exclusivity\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">Data exclusivity</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#Cost\"><span class=\"tocnumber\">1.3</span> <span class=\"toctext\">Cost</span></a></li>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#Lack_of_Generic_Brands\"><span class=\"tocnumber\">1.4</span> <span class=\"toctext\">Lack of Generic Brands</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#Legislation\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Legislation</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Trips_agreement\"><span class=\"tocnumber\">2.1</span> <span class=\"toctext\">Trips agreement</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#Doha_Declaration\"><span class=\"tocnumber\">2.2</span> <span class=\"toctext\">Doha Declaration</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-9\"><a href=\"#Paragraph_6_System\"><span class=\"tocnumber\">2.2.1</span> <span class=\"toctext\">Paragraph 6 System</span></a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#Differences_by_geography\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Differences by geography</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-11\"><a href=\"#Africa\"><span class=\"tocnumber\">3.1</span> <span class=\"toctext\">Africa</span></a></li>\n<li class=\"toclevel-2 tocsection-12\"><a href=\"#Latin_America\"><span class=\"tocnumber\">3.2</span> <span class=\"toctext\">Latin America</span></a></li>\n<li class=\"toclevel-2 tocsection-13\"><a href=\"#India\"><span class=\"tocnumber\">3.3</span> <span class=\"toctext\">India</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-14\"><a href=\"#Differences_by_sector\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Differences by sector</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-15\"><a href=\"#Vaccines\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">Vaccines</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-16\"><a href=\"#Epidemics_and_access\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">Epidemics and access</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-17\"><a href=\"#HIV/AIDs\"><span class=\"tocnumber\">5.1</span> <span class=\"toctext\">HIV/AIDs</span></a>\n<ul>\n<li class=\"toclevel-3 tocsection-18\"><a href=\"#Daraprim\"><span class=\"tocnumber\">5.1.1</span> <span class=\"toctext\">Daraprim</span></a></li>\n</ul>\n</li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-19\"><a href=\"#Campaigns\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Campaigns</span></a></li>\n<li class=\"toclevel-1 tocsection-20\"><a href=\"#See_also\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-21\"><a href=\"#References\"><span class=\"tocnumber\">8</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Hindrances_to_access\">Hindrances to access</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=1\" title=\"Edit section: Hindrances to access\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Most hindrances to access revolve around <a href=\"/wiki/Market_competition\" class=\"mw-redirect\" title=\"Market competition\">market competition</a> and lack of it.\n</p>\n<h3><span class=\"mw-headline\" id=\"Patent_protection_and_exclusivity\">Patent protection and exclusivity</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=2\" title=\"Edit section: Patent protection and exclusivity\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Patent\" title=\"Patent\">Patents</a> provide an owner <a href=\"/wiki/Exclusive_right\" title=\"Exclusive right\">exclusive rights</a> to a product or process for 20 years in a particular territory. The owner of the patent has the right to prevent the manufacture, use, sell, import, or distribution of the patented product.<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup> It is argued that <a href=\"/wiki/Patent_protection\" class=\"mw-redirect\" title=\"Patent protection\">patent protection</a> allows <a href=\"/wiki/Pharmaceutical_companies\" class=\"mw-redirect\" title=\"Pharmaceutical companies\">pharmaceutical companies</a> a <a href=\"/wiki/Monopoly\" title=\"Monopoly\">monopoly</a> on particular drugs and processes.<sup id=\"cite_ref-:0_6-0\" class=\"reference\"><a href=\"#cite_note-:0-6\">&#91;6&#93;</a></sup><sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Data_exclusivity\">Data exclusivity</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=3\" title=\"Edit section: Data exclusivity\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Data_exclusivity\" class=\"mw-redirect\" title=\"Data exclusivity\">Data exclusivity</a> is a regulatory measure limiting the use of <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">clinical trial</a> data and provides conductor of the trial temporary exclusive rights to the data.<sup id=\"cite_ref-:0_6-1\" class=\"reference\"><a href=\"#cite_note-:0-6\">&#91;6&#93;</a></sup> Many suggest that extending exclusivity periods can have consequences in delivering <a href=\"/wiki/Medication\" title=\"Medication\">medication</a>, especially <a href=\"/wiki/Generic_brand\" title=\"Generic brand\">generic brands</a>, to <a href=\"/wiki/Developing_country\" title=\"Developing country\">developing countries</a>. However, extending patent terms can be reinvested for <a href=\"/wiki/Research_and_development\" title=\"Research and development\">research and development</a> and/or a source of funding for drug donations to low-income countries.<sup id=\"cite_ref-:5_8-0\" class=\"reference\"><a href=\"#cite_note-:5-8\">&#91;8&#93;</a></sup> Others suggest that data exclusivity works to diminish the availability of <a href=\"/wiki/Generic_drug\" title=\"Generic drug\">generic drugs</a>. Many argue that pharmaceutical companies push for data exclusivity\u2014seeking to extend their monopolies by advocating for market exclusivity provided by patents and data exclusivity, or protection for new medicine.<sup id=\"cite_ref-:0_6-2\" class=\"reference\"><a href=\"#cite_note-:0-6\">&#91;6&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Cost\">Cost</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=4\" title=\"Edit section: Cost\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"/wiki/File:Martin_Shkreli_House_Committee_on_Oversight_and_Government_Reform_2016.jpg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/6f/Martin_Shkreli_House_Committee_on_Oversight_and_Government_Reform_2016.jpg/220px-Martin_Shkreli_House_Committee_on_Oversight_and_Government_Reform_2016.jpg\" width=\"220\" height=\"225\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/6/6f/Martin_Shkreli_House_Committee_on_Oversight_and_Government_Reform_2016.jpg 1.5x\" data-file-width=\"267\" data-file-height=\"273\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Martin_Shkreli_House_Committee_on_Oversight_and_Government_Reform_2016.jpg\" class=\"internal\" title=\"Enlarge\"></a></div>Martin Shkreli testifying before the House Committee on Oversight and Government Reform, 2016</div></div></div>\n<p>In some countries pharmaceutical company have ultimate control of the pricing of their patented product. Therefore, the owner has control of the pricing of the medication, based on the price level the owner deems best to reflects their ability to manufacture and the level of profit desired. Purchasers have little say over the price set.<sup id=\"cite_ref-:22_9-0\" class=\"reference\"><a href=\"#cite_note-:22-9\">&#91;9&#93;</a></sup> It is argued that competition is necessary to lower drug prices and improve access to affordable medications.<sup id=\"cite_ref-:6_10-0\" class=\"reference\"><a href=\"#cite_note-:6-10\">&#91;10&#93;</a></sup><sup id=\"cite_ref-:13_11-0\" class=\"reference\"><a href=\"#cite_note-:13-11\">&#91;11&#93;</a></sup>\n</p><p><a href=\"/wiki/Price_gouging\" title=\"Price gouging\">Price gouging</a> is defined as the excessive increase in prices by sellers of essential goods to a level deemed higher than reasonable or fair. This sharp increase in prices may leave the buyer vulnerable. It also leads to inequitable access to essential goods among different socioeconomic groups.<sup id=\"cite_ref-12\" class=\"reference\"><a href=\"#cite_note-12\">&#91;12&#93;</a></sup> It is argued that pharmaceutical companies have dramatically increased prices for treatments that are essential in treating diseases such as <a href=\"/wiki/HIV/AIDS\" title=\"HIV/AIDS\">HIV/AIDS</a>, <a href=\"/wiki/Hepatitis_C\" title=\"Hepatitis C\">hepatitis C</a>, and <a href=\"/wiki/Cancer\" title=\"Cancer\">cancer</a>.<sup id=\"cite_ref-13\" class=\"reference\"><a href=\"#cite_note-13\">&#91;13&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Lack_of_Generic_Brands\">Lack of Generic Brands</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=5\" title=\"Edit section: Lack of Generic Brands\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Many argue that generic brand production in developing countries increases competition and therefore is essential to bridge the global drug gap.<sup id=\"cite_ref-:13_11-1\" class=\"reference\"><a href=\"#cite_note-:13-11\">&#91;11&#93;</a></sup><sup id=\"cite_ref-:22_9-1\" class=\"reference\"><a href=\"#cite_note-:22-9\">&#91;9&#93;</a></sup> As argued by various sources, the push for more measures such as market and data exclusivity, hinders low-income countries' ability to manufacture and produce generic drugs.<sup id=\"cite_ref-:0_6-3\" class=\"reference\"><a href=\"#cite_note-:0-6\">&#91;6&#93;</a></sup> However, low-income countries often lack the essential <a href=\"/wiki/Infrastructure\" title=\"Infrastructure\">infrastructure</a> to allow for generic brand production.<sup id=\"cite_ref-:22_9-2\" class=\"reference\"><a href=\"#cite_note-:22-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-:5_8-1\" class=\"reference\"><a href=\"#cite_note-:5-8\">&#91;8&#93;</a></sup> In order the use of the medication to be effective, it must be manufactured in optimal laboratory conditions. Developing countries often lack air conditioning, stable electrical power, or refrigerators to store samples and chemicals.<sup id=\"cite_ref-:5_8-2\" class=\"reference\"><a href=\"#cite_note-:5-8\">&#91;8&#93;</a></sup> Also, quality generic brand production is limited by a government's ability to create effective spaces of market competition and to monitor the quality of generics brands; this ability has been found to be limited in certain developing countries.<sup id=\"cite_ref-14\" class=\"reference\"><a href=\"#cite_note-14\">&#91;14&#93;</a></sup>  It also argued that <a href=\"/wiki/International_aid\" class=\"mw-redirect\" title=\"International aid\">international aid</a>, state investment, and measures for infection prevention are necessary to allow for generic brand production in low-income countries.<sup id=\"cite_ref-:22_9-3\" class=\"reference\"><a href=\"#cite_note-:22-9\">&#91;9&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Legislation\">Legislation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=6\" title=\"Edit section: Legislation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"https://en.wikipedia.org/wiki/File:World%20Trade%20Organization%20(logo%20and%20wordmark).svg\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/f/f5/World_Trade_Organization_%28logo_and_wordmark%29.svg/220px-World_Trade_Organization_%28logo_and_wordmark%29.svg.png\" width=\"220\" height=\"66\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/f/f5/World_Trade_Organization_%28logo_and_wordmark%29.svg/330px-World_Trade_Organization_%28logo_and_wordmark%29.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/f5/World_Trade_Organization_%28logo_and_wordmark%29.svg/440px-World_Trade_Organization_%28logo_and_wordmark%29.svg.png 2x\" data-file-width=\"300\" data-file-height=\"90\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:World_Trade_Organization_(logo_and_wordmark).svg\" class=\"internal\" title=\"Enlarge\"></a></div>Logo of the World Trade Organization (WTO)</div></div></div>\n<h3><span class=\"mw-headline\" id=\"Trips_agreement\">Trips agreement</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=7\" title=\"Edit section: Trips agreement\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The <a href=\"/wiki/TRIPS_Agreement\" title=\"TRIPS Agreement\">Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)</a>, is a multilateral agreement between all member nations of the <a href=\"/wiki/World_Trade_Organization\" title=\"World Trade Organization\">World Trade Organization</a> (WTO), effective January 1995.<sup id=\"cite_ref-15\" class=\"reference\"><a href=\"#cite_note-15\">&#91;15&#93;</a></sup> This agreement introduced global standards for enforcing and protecting nearly all forms of <a href=\"/wiki/Intellectual_Property_Rights\" class=\"mw-redirect\" title=\"Intellectual Property Rights\">intellectual property rights</a> (IPR), including those for patents and data protection. Under the TRIPS Agreement, WTO member nations, with a few exceptions, are required to adjust their laws to the minimum standards of IPR protection. Member nations are also obligated to follow specific <a href=\"/wiki/Enforcement\" title=\"Enforcement\">enforcement</a> guidelines, remedies, and <a href=\"/wiki/Dispute_resolution\" title=\"Dispute resolution\">dispute resolution</a> procedures. Before TRIPS, other international conventions and laws did not specify minimum standards for <a href=\"/wiki/Intellectual_property_laws\" class=\"mw-redirect\" title=\"Intellectual property laws\">intellectual property laws</a> in the <a href=\"/wiki/International_trading_system\" class=\"mw-redirect\" title=\"International trading system\">international trading system</a>. The TRIPS Agreement is argued to have the greatest effect on the pharmaceutical industry and access to medicines.<sup id=\"cite_ref-16\" class=\"reference\"><a href=\"#cite_note-16\">&#91;16&#93;</a></sup> It is argued that the TRIPS agreement negatively impacted generic drug industries in countries such as India. However, others argue that the agreement is open to interpretation. A clause in the TRIPS agreement allows <a href=\"/wiki/Compulsory_license\" title=\"Compulsory license\">compulsory licensing</a>, which permits the manufacture of generic brands of patented drugs, at prices set in a competitive market in cases of national emergencies.<sup id=\"cite_ref-:22_9-4\" class=\"reference\"><a href=\"#cite_note-:22-9\">&#91;9&#93;</a></sup> For example, many believe that the HIV/AIDs crisis in <a href=\"/wiki/Africa\" title=\"Africa\">Africa</a> and <a href=\"/wiki/Southeast_Asia\" title=\"Southeast Asia\">South East Asia</a> and the inadequate access to essential AIDs medications constitute a national emergency. Therefore, the TRIPS Agreement can be interpreted to allow the manufacture of generic brands of patented HIV/AIDs drugs<sup id=\"cite_ref-:22_9-5\" class=\"reference\"><a href=\"#cite_note-:22-9\">&#91;9&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Doha_Declaration\">Doha Declaration</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=8\" title=\"Edit section: Doha Declaration\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Further legislation such as <a href=\"/wiki/Doha_Declaration\" title=\"Doha Declaration\">Doha Declaration</a> of 2001 worked to rectify the negative impact of the TRIPS Agreement.<sup id=\"cite_ref-:3_17-0\" class=\"reference\"><a href=\"#cite_note-:3-17\">&#91;17&#93;</a></sup> The Doha Declaration on the TRIPS Agreement and Public Health, effective November 2001, was adopted by  <a href=\"/wiki/WTO_Ministerial_Conference_of_2001\" class=\"mw-redirect\" title=\"WTO Ministerial Conference of 2001\">WTO Ministerial Conference of 2001</a>. Many argued that the TRIPS Agreement hindered developing countries from implementing measures to improve access to affordable medicines, especially for diseases of public health concern, such as <a href=\"/wiki/HIV/AIDS\" title=\"HIV/AIDS\">HIV,</a> <a href=\"/wiki/Tuberculosis\" title=\"Tuberculosis\">tuberculosis</a>, and <a href=\"/wiki/Malaria\" title=\"Malaria\">malaria</a>. The Doha Declaration responds to concerns of developing countries that patent protection rules and other IPRs were hindering access to affordable medicines for populations in those countries.<sup id=\"cite_ref-:4_18-0\" class=\"reference\"><a href=\"#cite_note-:4-18\">&#91;18&#93;</a></sup> The Doha Declaration emphasizes the flexibility of the TRIPS Agreement and highlights the right of respective government to interpret the TRIPS Agreement in terms of public health. It refers to specific parts of TRIPS, such as the use of compulsory licensing for <a href=\"/wiki/Pharmaceutical_drugs\" class=\"mw-redirect\" title=\"Pharmaceutical drugs\">pharmaceutical drugs</a> only in the case of a national emergency and circumstances of extreme urgency  and the right to determine what constitutes this\u2014such as to address <a href=\"/wiki/Public_health\" title=\"Public health\">public health</a> issues.<sup id=\"cite_ref-:4_18-1\" class=\"reference\"><a href=\"#cite_note-:4-18\">&#91;18&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Paragraph_6_System\">Paragraph 6 System</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=9\" title=\"Edit section: Paragraph 6 System\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<p>The declaration also allows for countries without manufacturing capabilities to turn to another country for the export of generic brands of patented medicines.<sup id=\"cite_ref-19\" class=\"reference\"><a href=\"#cite_note-19\">&#91;19&#93;</a></sup><sup id=\"cite_ref-:3_17-1\" class=\"reference\"><a href=\"#cite_note-:3-17\">&#91;17&#93;</a></sup> This is known as the paragraph 6 system.<sup id=\"cite_ref-chungp6_20-0\" class=\"reference\"><a href=\"#cite_note-chungp6-20\">&#91;20&#93;</a></sup> As of 2010 it had only been called upon once, concerning the export of medicines from Canada to Rwanda, with varying opinions about its results and potential.<sup id=\"cite_ref-chungp6_20-1\" class=\"reference\"><a href=\"#cite_note-chungp6-20\">&#91;20&#93;</a></sup><sup id=\"cite_ref-21\" class=\"reference\"><a href=\"#cite_note-21\">&#91;21&#93;</a></sup><sup id=\"cite_ref-22\" class=\"reference\"><a href=\"#cite_note-22\">&#91;22&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Differences_by_geography\">Differences by geography</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=10\" title=\"Edit section: Differences by geography\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"https://en.wikipedia.org/wiki/File:AIDS%20and%20HIV%20prevalence%202009.svg\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/be/AIDS_and_HIV_prevalence_2009.svg/220px-AIDS_and_HIV_prevalence_2009.svg.png\" width=\"220\" height=\"112\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/b/be/AIDS_and_HIV_prevalence_2009.svg/330px-AIDS_and_HIV_prevalence_2009.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/be/AIDS_and_HIV_prevalence_2009.svg/440px-AIDS_and_HIV_prevalence_2009.svg.png 2x\" data-file-width=\"940\" data-file-height=\"477\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:AIDS_and_HIV_prevalence_2009.svg\" class=\"internal\" title=\"Enlarge\"></a></div>HIV/AIDS prevalence world map in 2009 according to <a href=\"/wiki/UNAIDS\" class=\"mw-redirect\" title=\"UNAIDS\">UNAIDS</a> data</div></div></div>\n<h3><span class=\"mw-headline\" id=\"Africa\">Africa</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=11\" title=\"Edit section: Africa\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>There is estimated to be more than 4 million HIV infected individuals in <a href=\"/wiki/South_Africa\" title=\"South Africa\">South Africa</a>. Out of this, only 10,000 individuals are able to afford access to essential <a href=\"/wiki/AIDS_medication\" class=\"mw-redirect\" title=\"AIDS medication\">AIDS medications</a> at their current prices. In <a href=\"/wiki/Malawi\" title=\"Malawi\">Malawi</a>, out of one million infected individuals, 30 have access to life-sustaining essential AIDS medications.<sup id=\"cite_ref-:22_9-6\" class=\"reference\"><a href=\"#cite_note-:22-9\">&#91;9&#93;</a></sup> In <a href=\"/wiki/Uganda\" title=\"Uganda\">Uganda</a>, out of the estimated 820,000 infected individuals, only about 1.2% can afford essential AIDS medications.<sup id=\"cite_ref-23\" class=\"reference\"><a href=\"#cite_note-23\">&#91;23&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Latin_America\">Latin America</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=12\" title=\"Edit section: Latin America\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>There is estimated to be 1.8 million individuals HIV infected individuals in the <a href=\"/wiki/Latin_America\" title=\"Latin America\">Latin American</a> region. Brazil is argued to be one of the most affected by the <a href=\"/wiki/AIDS_epidemic\" class=\"mw-redirect\" title=\"AIDS epidemic\">AIDS epidemic</a>. There is also a high prevalence of HIV in smaller countries such as <a href=\"/wiki/Guatemala\" title=\"Guatemala\">Guatemala</a>, <a href=\"/wiki/Honduras\" title=\"Honduras\">Honduras</a>, and <a href=\"/wiki/Belize\" title=\"Belize\">Belize</a>.<sup id=\"cite_ref-24\" class=\"reference\"><a href=\"#cite_note-24\">&#91;24&#93;</a></sup> However, Brazil is argued not to have restrictive patent laws. In the mid 1990s, Brazil began manufacturing generic brands of vital AIDS medication. Due to this, Brazil's AIDS mortality rate declined by almost 50%.<sup id=\"cite_ref-:22_9-7\" class=\"reference\"><a href=\"#cite_note-:22-9\">&#91;9&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"India\">India</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=13\" title=\"Edit section: India\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Many Indian families live below the poverty line due to healthcare expenses. From 1972 to 2005, due to a lack of <a href=\"/wiki/Patent_laws\" class=\"mw-redirect\" title=\"Patent laws\">patent laws</a> for drugs in India, Indian drug companies were able to use alternative, legal processes to manufacture generic versions of drugs. These generic drug companies were able to produce low-priced drugs that were considered among the lowest in the world. This allowed India to provide free antiretroviral treatment to 340,000 HIV infected individuals in the country. Majority of adult antiretroviral drugs purchased for donor-funded programs in developing countries were supplied by Indian generic drug companies. In compliance to the <a href=\"/wiki/TRIPS_Agreement\" title=\"TRIPS Agreement\">Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)</a>, India reintroduced patent laws for drugs in 2015.<sup id=\"cite_ref-:6_10-1\" class=\"reference\"><a href=\"#cite_note-:6-10\">&#91;10&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Differences_by_sector\">Differences by sector</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=14\" title=\"Edit section: Differences by sector\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Vaccines\">Vaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=15\" title=\"Edit section: Vaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The majority of deaths from <a href=\"/wiki/Vaccine-preventable_diseases\" title=\"Vaccine-preventable diseases\">vaccine-preventable diseases</a> occur in low and middle income countries. In low-income countries, more than 90% of deaths are from <a href=\"/wiki/Streptococcus_pneumoniae\" title=\"Streptococcus pneumoniae\">pneumococcal disease</a>, 95% from <a href=\"/wiki/Haemophilus_influenzae\" title=\"Haemophilus influenzae\">Hib</a>, and 80% from <a href=\"/wiki/Hepatitis_B\" title=\"Hepatitis B\">hepatitis B</a>. Although widely used by high-income countries, in 2006, Hib <a href=\"/wiki/Vaccine\" title=\"Vaccine\">vaccine</a> usage in Africa was about 24% In the Americas, <a href=\"/wiki/Hepatitis_B_vaccine\" title=\"Hepatitis B vaccine\">Hepatitis B vaccine</a> usage was at 90%. In Southeast Asia, where there is hepatitis B epidemic, the <a href=\"/wiki/Hib_vaccine\" title=\"Hib vaccine\">Hib vaccine</a> coverage was only 28%. The <a href=\"/wiki/Human_papillomavirus_infection\" title=\"Human papillomavirus infection\">human papillomavirus (HPV)</a> vaccine is considered the most expensive vaccine in history. However, the majority of those that suffer from <a href=\"/wiki/Cervical_cancer\" title=\"Cervical cancer\">cervical cancer</a> are in developing countries.<sup id=\"cite_ref-:13_11-2\" class=\"reference\"><a href=\"#cite_note-:13-11\">&#91;11&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Epidemics_and_access\">Epidemics and access</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=16\" title=\"Edit section: Epidemics and access\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span id=\"HIV.2FAIDs\"></span><span class=\"mw-headline\" id=\"HIV/AIDs\">HIV/AIDs</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=17\" title=\"Edit section: HIV/AIDs\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The appearance of generic manufacturers in low-income countries, such as <a href=\"/wiki/India\" title=\"India\">India</a> and <a href=\"/wiki/Brazil\" title=\"Brazil\">Brazil</a>, was key to increasing access to <a href=\"/wiki/HIV/AIDS_treatment\" class=\"mw-redirect\" title=\"HIV/AIDS treatment\">HIV/AIDS treatment</a> in low- and middle- income countries (LMICs). Due to the introduction of generic brand competition, first-line <a href=\"/wiki/Antiretroviral\" class=\"mw-redirect\" title=\"Antiretroviral\">antiretroviral</a> drugs' prices dropped by more than 99%, from $10,000/year per patient in 2000 to less than $70 in 2014.<sup id=\"cite_ref-:13_11-3\" class=\"reference\"><a href=\"#cite_note-:13-11\">&#91;11&#93;</a></sup>\n</p>\n<h4><span class=\"mw-headline\" id=\"Daraprim\">Daraprim</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=18\" title=\"Edit section: Daraprim\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h4>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"https://en.wikipedia.org/wiki/File:5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine%20200.svg\"><img alt=\"Structure of 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/5/56/5-%284-chlorophenyl%29-6-ethylpyrimidine-2%2C4-diamine_200.svg/220px-5-%284-chlorophenyl%29-6-ethylpyrimidine-2%2C4-diamine_200.svg.png\" width=\"220\" height=\"125\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/5/56/5-%284-chlorophenyl%29-6-ethylpyrimidine-2%2C4-diamine_200.svg/330px-5-%284-chlorophenyl%29-6-ethylpyrimidine-2%2C4-diamine_200.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/56/5-%284-chlorophenyl%29-6-ethylpyrimidine-2%2C4-diamine_200.svg/440px-5-%284-chlorophenyl%29-6-ethylpyrimidine-2%2C4-diamine_200.svg.png 2x\" data-file-width=\"218\" data-file-height=\"124\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine_200.svg\" class=\"internal\" title=\"Enlarge\"></a></div>The chemical structure of <a href=\"/wiki/Pyrimethamine\" title=\"Pyrimethamine\">pyrimethamine</a>, commonly known as Daraprim</div></div></div>\n<p>On August 10, 2015, <a href=\"/wiki/Turing_Pharmaceuticals\" title=\"Turing Pharmaceuticals\">Turig Pharmaceuticals</a>, a pharmaceutical company owned by <a href=\"/wiki/Martin_Shkreli\" title=\"Martin Shkreli\">Martin Shkreli</a>, purchased the rights to a <a href=\"/wiki/Daraprim\" class=\"mw-redirect\" title=\"Daraprim\">Daraprim</a>.<sup id=\"cite_ref-25\" class=\"reference\"><a href=\"#cite_note-25\">&#91;25&#93;</a></sup> Daraprim, an <a href=\"/wiki/Antiparasitic\" title=\"Antiparasitic\">anti-parasitic</a> and <a href=\"/wiki/Antimalarial_medication\" title=\"Antimalarial medication\">anti-malarial</a> drug, is considered an essential drug for HIV treatments. It is widely used to treat patients with AIDS-related and AIDs-unrelated <a href=\"/wiki/Toxoplasmosis\" title=\"Toxoplasmosis\">toxoplasmosis</a>.<sup id=\"cite_ref-26\" class=\"reference\"><a href=\"#cite_note-26\">&#91;26&#93;</a></sup> At the time, no other generic versions of the drug was available. Turig dramatically raised the price of the drug from $13.50 a tablet to $750, a 5000% increase.<sup id=\"cite_ref-27\" class=\"reference\"><a href=\"#cite_note-27\">&#91;27&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Campaigns\">Campaigns</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=19\" title=\"Edit section: Campaigns\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>A number of countries and organizations have efforts to improve access to medicines in specific areas of the world.\n</p><p>The <a href=\"/wiki/Canada%27s_Access_to_Medicines_Regime\" title=\"Canada&#39;s Access to Medicines Regime\">Canada's Access to Medicines Regime</a> allows developing countries to bring in medicines at lower cost.<sup id=\"cite_ref-28\" class=\"reference\"><a href=\"#cite_note-28\">&#91;28&#93;</a></sup> It specifically allows companies in Canada who may not own the right to make a medication to do so for export to certain countries in the developing world.<sup id=\"cite_ref-29\" class=\"reference\"><a href=\"#cite_note-29\">&#91;29&#93;</a></sup>\n</p><p><a href=\"/wiki/M%C3%A9decins_Sans_Fronti%C3%A8res\" title=\"M\u00e9decins Sans Fronti\u00e8res\">M\u00e9decins Sans Fronti\u00e8res</a> has had such a campaign since 1999 known as the <a href=\"/wiki/Campaign_for_Access_to_Essential_Medicines\" title=\"Campaign for Access to Essential Medicines\">Campaign for Access to Essential Medicines</a>.<sup id=\"cite_ref-30\" class=\"reference\"><a href=\"#cite_note-30\">&#91;30&#93;</a></sup>\n</p><p>In <a href=\"/wiki/Tanzania\" title=\"Tanzania\">Tanzania</a>, the Ministry of Health and the Tanzania Food and Drugs Authority and the Strategies for Enhancing Access to Medicines Program introduced accredited drug dispensing outlets, with aid from <a href=\"/wiki/Bill_%26_Melinda_Gates_Foundation\" title=\"Bill &amp; Melinda Gates Foundation\">Bill &amp; Melinda Gates Foundation</a>. It worked to create a nationwide chain of dispensers, which provide quality pharmaceutical drugs and services to its citizens.<sup id=\"cite_ref-31\" class=\"reference\"><a href=\"#cite_note-31\">&#91;31&#93;</a></sup>\n</p><p><a href=\"/wiki/Gavi,_the_Vaccine_Alliance\" title=\"Gavi, the Vaccine Alliance\">Gavi, the Vaccine Alliance</a> is an international <a href=\"/wiki/Public%E2%80%93private_partnership\" title=\"Public\u2013private partnership\">public-private</a> partnership, created in 2000, devoted to improving access to vaccines in low-income countries.<sup id=\"cite_ref-32\" class=\"reference\"><a href=\"#cite_note-32\">&#91;32&#93;</a></sup> The organization partners with several developing countries, donor governments, research agencies, and vaccines companies in both in industrialized and developing countries. It also partners with organizations such as the <a href=\"/wiki/World_Health_Organization\" title=\"World Health Organization\">World Health Organization</a>, <a href=\"/wiki/UNICEF\" title=\"UNICEF\">UNICEF</a>, the <a href=\"/wiki/World_Bank\" title=\"World Bank\">World Bank</a>, the <a href=\"/wiki/Bill_%26_Melinda_Gates_Foundation\" title=\"Bill &amp; Melinda Gates Foundation\">Bill &amp; Melinda Gates Foundation</a> and other private philanthropists.<sup id=\"cite_ref-33\" class=\"reference\"><a href=\"#cite_note-33\">&#91;33&#93;</a></sup> Gavi is noted as an important source of external funding for vaccines in low-income countries and played a crucial role in introducing the HPV vaccine and other new vaccines to developing countries.<sup id=\"cite_ref-:13_11-4\" class=\"reference\"><a href=\"#cite_note-:13-11\">&#91;11&#93;</a></sup>\n</p><p>In <a href=\"/wiki/Kenya\" title=\"Kenya\">Kenya</a>, the Kenya Coalition for Access to Essential Medicines (KCAEM), was formed in response to Kenya's Industrial Property Act 2001. The act outlined the rights of patent holders. Members of this coalition are local community-based and national NGOs, international NGOs, healthcare providers, journalists, lawyers and other individuals. The coalition works primarily with people living with HIV/AIDS and access to essential HIV/AIDS medications and treatments.<sup id=\"cite_ref-:7_34-0\" class=\"reference\"><a href=\"#cite_note-:7-34\">&#91;34&#93;</a></sup> It urges for flexibility in interpreting the TRIPS Agreement and efforts to implement production of generic antiretroviral drugs by local manufacturers and/or to import inexpensive drugs.<sup id=\"cite_ref-35\" class=\"reference\"><a href=\"#cite_note-35\">&#91;35&#93;</a></sup> It also calls for pharmaceutical companies to reduce the price of their medications.<sup id=\"cite_ref-36\" class=\"reference\"><a href=\"#cite_note-36\">&#91;36&#93;</a></sup> The coalition has garnered support from key government officials and organizations such as Kenyan Property Institute, Kenyan Ministry of Trade, and the Minister of Trade Mr. Nicholas Biwott MP.<sup id=\"cite_ref-:7_34-1\" class=\"reference\"><a href=\"#cite_note-:7-34\">&#91;34&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=20\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/WHO_Model_List_of_Essential_Medicines\" title=\"WHO Model List of Essential Medicines\">WHO Model List of Essential Medicines</a></li>\n<li><a href=\"/wiki/Access_to_Medicine_Index\" title=\"Access to Medicine Index\">Access to Medicine Index</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Access_to_medicines&amp;action=edit&amp;section=21\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap mw-references-columns\"><ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/mediacentre/news/statements/2009/access-medicines-20090313/en/\">\"WHO Access to medicines\"</a>. <i>www.who.int</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2017-02-10</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.who.int&amp;rft.atitle=WHO+Access+to+medicines&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fmediacentre%2Fnews%2Fstatements%2F2009%2Faccess-medicines-20090313%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-WHO2017-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-WHO2017_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-WHO2017_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/medicines/areas/human_rights/en/\">\"Access to essential medicines as part of the right to health\"</a>. <i>World Health Organization</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 February</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization&amp;rft.atitle=Access+to+essential+medicines+as+part+of+the+right+to+health&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fmedicines%2Fareas%2Fhuman_rights%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.unsgaccessmeds.org/final-report\">\"Final Report High-Level Panel on Access to Medicines\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 February</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Final+Report+High-Level+Panel+on+Access+to+Medicines&amp;rft_id=http%3A%2F%2Fwww.unsgaccessmeds.org%2Ffinal-report&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Moon, Suerie (9 February 2017). \"Powerful Ideas for Global Access to Medicines\". <i>New England Journal of Medicine</i>. <b>376</b> (6): 505\u2013507. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1056/NEJMp1613861\">10.1056/NEJMp1613861</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+England+Journal+of+Medicine&amp;rft.atitle=Powerful+Ideas+for+Global+Access+to+Medicines&amp;rft.volume=376&amp;rft.issue=6&amp;rft.pages=505-507&amp;rft.date=2017-02-09&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMp1613861&amp;rft.aulast=Moon&amp;rft.aufirst=Suerie&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">. Leevy, Tara. <a rel=\"nofollow\" class=\"external text\" href=\"http://journalofethics.ama-assn.org/2006/12/hlaw1-0612.html\">\"Intellectual Property and Access to Medicine for the Poor\"</a>. <i>Virtual Mentor</i>. <b>8</b> (12): 834\u2013838. 2006-12-01. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1001/virtualmentor.2006.8.12.hlaw1-0612\">10.1001/virtualmentor.2006.8.12.hlaw1-0612</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Virtual+Mentor&amp;rft.atitle=Intellectual+Property+and+Access+to+Medicine+for+the+Poor&amp;rft.volume=8&amp;rft.issue=12&amp;rft.pages=834-838&amp;rft.date=2006-12-01&amp;rft_id=info%3Adoi%2F10.1001%2Fvirtualmentor.2006.8.12.hlaw1-0612&amp;rft_id=http%3A%2F%2Fjournalofethics.ama-assn.org%2F2006%2F12%2Fhlaw1-0612.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:0-6\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:0_6-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:0_6-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:0_6-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:0_6-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Diependaele, Lisa; Cockbain, Julian; Sterckx, Sigrid (April 2017). \"Raising the Barriers to Access to Medicines in the Developing World \u2013 The Relentless Push for Data Exclusivity\". <i>Developing World Bioethics</i>. <b>17</b> (1): 11\u201321.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Developing+World+Bioethics&amp;rft.atitle=Raising+the+Barriers+to+Access+to+Medicines+in+the+Developing+World+%E2%80%93+The+Relentless+Push+for+Data+Exclusivity&amp;rft.volume=17&amp;rft.issue=1&amp;rft.pages=11-21&amp;rft.date=2017-04&amp;rft.aulast=Diependaele&amp;rft.aufirst=Lisa&amp;rft.au=Cockbain%2C+Julian&amp;rft.au=Sterckx%2C+Sigrid&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">M.D., Robert Pearl,. <a rel=\"nofollow\" class=\"external text\" href=\"https://www.forbes.com/sites/robertpearl/2017/01/19/why-patent-protection-in-the-drug-industry-is-out-of-control/#97d25fa78ca9\">\"Why Patent Protection In The Drug Industry Is Out Of Control\"</a>. <i>Forbes</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Forbes&amp;rft.atitle=Why+Patent+Protection+In+The+Drug+Industry+Is+Out+Of+Control&amp;rft.aulast=M.D.&amp;rft.aufirst=Robert+Pearl%2C&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Frobertpearl%2F2017%2F01%2F19%2Fwhy-patent-protection-in-the-drug-industry-is-out-of-control%2F%2397d25fa78ca9&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:5-8\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:5_8-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:5_8-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:5_8-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Stevens, Hilde; Huys, Isabelle. <a rel=\"nofollow\" class=\"external text\" href=\"https://dx.doi.org.ezproxy.neu.edu/10.3389/fmed.2017.00218\">\"Innovative Approaches to Increase Access to Medicines in Developing Countries\"</a>. <i>Frontiers in Medicine</i>. <b>4</b>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3389/fmed.2017.00218\">10.3389/fmed.2017.00218</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Frontiers+in+Medicine&amp;rft.atitle=Innovative+Approaches+to+Increase+Access+to+Medicines+in+Developing+Countries&amp;rft.volume=4&amp;rft_id=info%3Adoi%2F10.3389%2Ffmed.2017.00218&amp;rft.aulast=Stevens&amp;rft.aufirst=Hilde&amp;rft.au=Huys%2C+Isabelle&amp;rft_id=https%3A%2F%2Fdx.doi.org.ezproxy.neu.edu%2F10.3389%2Ffmed.2017.00218&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:22-9\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:22_9-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:22_9-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:22_9-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:22_9-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-:22_9-4\"><sup><i><b>e</b></i></sup></a> <a href=\"#cite_ref-:22_9-5\"><sup><i><b>f</b></i></sup></a> <a href=\"#cite_ref-:22_9-6\"><sup><i><b>g</b></i></sup></a> <a href=\"#cite_ref-:22_9-7\"><sup><i><b>h</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Sch\u00fcklenk, Udo; Ashcroft, Richard E. (April 2002). \"Affordable Access to Essential Medication in Developing Countries: ConflictsBetween Ethical and Economic Imperatives\". <i>Journal of Medicine &amp; Philosophy</i>. <b>27</b> (2): 179\u201395.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Medicine+%26+Philosophy&amp;rft.atitle=Affordable+Access+to+Essential+Medication+in+Developing+Countries%3A+ConflictsBetween+Ethical+and+Economic+Imperatives&amp;rft.volume=27&amp;rft.issue=2&amp;rft.pages=179-95&amp;rft.date=2002-04&amp;rft.aulast=Sch%C3%BCklenk&amp;rft.aufirst=Udo&amp;rft.au=Ashcroft%2C+Richard+E.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:6-10\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:6_10-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:6_10-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Grover, Anand; Citro, Brian. <a rel=\"nofollow\" class=\"external text\" href=\"http://linkinghub.elsevier.com/retrieve/pii/S0140673610620429\">\"India: access to affordable drugs and the right to health\"</a>. <i>The Lancet</i>. <b>377</b> (9770): 976\u2013977. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/s0140-6736%2810%2962042-9\">10.1016/s0140-6736(10)62042-9</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Lancet&amp;rft.atitle=India%3A+access+to+affordable+drugs+and+the+right+to+health&amp;rft.volume=377&amp;rft.issue=9770&amp;rft.pages=976-977&amp;rft_id=info%3Adoi%2F10.1016%2Fs0140-6736%2810%2962042-9&amp;rft.aulast=Grover&amp;rft.aufirst=Anand&amp;rft.au=Citro%2C+Brian&amp;rft_id=http%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0140673610620429&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:13-11\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:13_11-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:13_11-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-:13_11-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-:13_11-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-:13_11-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Crager, Sara Eve. <a rel=\"nofollow\" class=\"external text\" href=\"https://dx.doi.org.ezproxy.neu.edu/10.2105/AJPH.2014.302236\">\"Improving Global Access to New Vaccines: Intellectual Property, Technology Transfer, and Regulatory Pathways\"</a>. <i>American Journal of Public Health</i>. <b>104</b> (11): e85\u2013e91. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.2105/ajph.2014.302236\">10.2105/ajph.2014.302236</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=American+Journal+of+Public+Health&amp;rft.atitle=Improving+Global+Access+to+New+Vaccines%3A+Intellectual+Property%2C+Technology+Transfer%2C+and+Regulatory+Pathways&amp;rft.volume=104&amp;rft.issue=11&amp;rft.pages=e85-e91&amp;rft_id=info%3Adoi%2F10.2105%2Fajph.2014.302236&amp;rft.aulast=Crager&amp;rft.aufirst=Sara+Eve&amp;rft_id=https%3A%2F%2Fdx.doi.org.ezproxy.neu.edu%2F10.2105%2FAJPH.2014.302236&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-12\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-12\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Weiss, Shira (2017-03-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://onlinelibrary.wiley.com/doi/10.1111/jore.12171/abstract\">\"The Ethics of Price Gouging\"</a>. <i>Journal of Religious Ethics</i>. <b>45</b> (1): 142\u2013163. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/jore.12171\">10.1111/jore.12171</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1467-9795\">1467-9795</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Religious+Ethics&amp;rft.atitle=The+Ethics+of+Price+Gouging&amp;rft.volume=45&amp;rft.issue=1&amp;rft.pages=142-163&amp;rft.date=2017-03-01&amp;rft_id=info%3Adoi%2F10.1111%2Fjore.12171&amp;rft.issn=1467-9795&amp;rft.aulast=Weiss&amp;rft.aufirst=Shira&amp;rft_id=http%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Fjore.12171%2Fabstract&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-13\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">\"DELAURO HOLDS COMMITTEE HEARING ON PRESCRIPTION DRUGS UNCONSCIONABLE PRICE GOUGING IS IMPEDING CARE AND INCREASING OVERALL HEALTH CARE COSTS\". <i>States News Service</i>. 2 December 2015.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=States+News+Service&amp;rft.atitle=DELAURO+HOLDS+COMMITTEE+HEARING+ON+PRESCRIPTION+DRUGS+UNCONSCIONABLE+PRICE+GOUGING+IS+IMPEDING+CARE+AND+INCREASING+OVERALL+HEALTH+CARE+COSTS&amp;rft.date=2015-12-02&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-14\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-14\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Godoy, Angelina Snodgrass (2015-06-01). <a rel=\"nofollow\" class=\"external text\" href=\"https://link.springer.com/article/10.1007/s12116-015-9184-4\">\"Market Myths and Assumptions: Examining the Transnational Politics of Access to Medicines Campaigning in Central America\"</a>. <i>Studies in Comparative International Development</i>. <b>50</b> (2): 187\u2013202. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/s12116-015-9184-4\">10.1007/s12116-015-9184-4</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/0039-3606\">0039-3606</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Studies+in+Comparative+International+Development&amp;rft.atitle=Market+Myths+and+Assumptions%3A+Examining+the+Transnational+Politics+of+Access+to+Medicines+Campaigning+in+Central+America&amp;rft.volume=50&amp;rft.issue=2&amp;rft.pages=187-202&amp;rft.date=2015-06-01&amp;rft_id=info%3Adoi%2F10.1007%2Fs12116-015-9184-4&amp;rft.issn=0039-3606&amp;rft.aulast=Godoy&amp;rft.aufirst=Angelina+Snodgrass&amp;rft_id=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12116-015-9184-4&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-15\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm\">\"WTO | intellectual property - overview of TRIPS Agreement\"</a>. <i>www.wto.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.wto.org&amp;rft.atitle=WTO+%7C+intellectual+property+-+overview+of+TRIPS+Agreement&amp;rft_id=https%3A%2F%2Fwww.wto.org%2Fenglish%2Ftratop_e%2Ftrips_e%2Fintel2_e.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-16\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/medicines/areas/policy/wto_trips/en/\">\"WTO AND THE TRIPS AGREEMENT\"</a>. <i>World Health Organization</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization&amp;rft.atitle=WTO+AND+THE+TRIPS+AGREEMENT&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fmedicines%2Fareas%2Fpolicy%2Fwto_trips%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:3-17\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:3_17-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:3_17-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Cohen-Kohler, J C (2007-11-01). <a rel=\"nofollow\" class=\"external text\" href=\"http://onlinelibrary.wiley.com/doi/10.1038/sj.clpt.6100359/abstract\">\"The Morally Uncomfortable Global Drug Gap\"</a>. <i>Clinical Pharmacology &amp; Therapeutics</i>. <b>82</b> (5): 610\u2013614. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/sj.clpt.6100359\">10.1038/sj.clpt.6100359</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1532-6535\">1532-6535</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Clinical+Pharmacology+%26+Therapeutics&amp;rft.atitle=The+Morally+Uncomfortable+Global+Drug+Gap&amp;rft.volume=82&amp;rft.issue=5&amp;rft.pages=610-614&amp;rft.date=2007-11-01&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.clpt.6100359&amp;rft.issn=1532-6535&amp;rft.aulast=Cohen-Kohler&amp;rft.aufirst=J+C&amp;rft_id=http%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1038%2Fsj.clpt.6100359%2Fabstract&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:4-18\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:4_18-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:4_18-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/medicines/areas/policy/doha_declaration/en/\">\"THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND PUBLIC HEALTH\"</a>. <i>World Health Organization</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=World+Health+Organization&amp;rft.atitle=THE+DOHA+DECLARATION+ON+THE+TRIPS+AGREEMENT+AND+PUBLIC+HEALTH&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fmedicines%2Fareas%2Fpolicy%2Fdoha_declaration%2Fen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-19\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.wto.org/english/thewto_e/glossary_e/paragraph6_e.htm\">\"WTO | Glossary - Paragraph 6 system\"</a>. <i>www.wto.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-04-27</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.wto.org&amp;rft.atitle=WTO+%7C+Glossary+-+Paragraph+6+system&amp;rft_id=https%3A%2F%2Fwww.wto.org%2Fenglish%2Fthewto_e%2Fglossary_e%2Fparagraph6_e.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-chungp6-20\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-chungp6_20-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-chungp6_20-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">Chung, Laura (Fall 2010). \"Use of Paragraph 6 System for Access to Medicine\". <i>North Carolina Journal of International Law &amp; Commercial Regulation</i>. <b>36</b>: 137\u2013186.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=North+Carolina+Journal+of+International+Law+%26+Commercial+Regulation&amp;rft.atitle=Use+of+Paragraph+6+System+for+Access+to+Medicine.&amp;rft.ssn=fall&amp;rft.volume=36&amp;rft.pages=137-186&amp;rft.date=2010&amp;rft.aulast=Chung&amp;rft.aufirst=Laura&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-21\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Abbas, Muhammad Z.; Riaz, Shamreeza (2017-11-24). <a rel=\"nofollow\" class=\"external text\" href=\"http://doi.wiley.com/10.1111/jwip.12083\">\"WTO \"Paragraph 6\" system for affordable access to medicines: Relief or regulatory ritualism?\"</a>. <i>The Journal of World Intellectual Property</i>. <b>21</b> (1-2): 32\u201351. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1111/jwip.12083\">10.1111/jwip.12083</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1422-2213\">1422-2213</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Journal+of+World+Intellectual+Property&amp;rft.atitle=WTO+%22Paragraph+6%22+system+for+affordable+access+to+medicines%3A+Relief+or+regulatory+ritualism%3F&amp;rft.volume=21&amp;rft.issue=1-2&amp;rft.pages=32-51&amp;rft.date=2017-11-24&amp;rft_id=info%3Adoi%2F10.1111%2Fjwip.12083&amp;rft.issn=1422-2213&amp;rft.aulast=Abbas&amp;rft.aufirst=Muhammad+Z.&amp;rft.au=Riaz%2C+Shamreeza&amp;rft_id=http%3A%2F%2Fdoi.wiley.com%2F10.1111%2Fjwip.12083&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-22\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Owoeye, Olasupo (2015). \"International Patents Law and Public Health: Revisiting the TRIPS Compulsory Licensing Regime and the Doha Paragraph 6 System\". <i>European Intellectual Property Review</i>. <b>37</b>: 782\u2013795.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=European+Intellectual+Property+Review&amp;rft.atitle=International+Patents+Law+and+Public+Health%3A+Revisiting+the+TRIPS+Compulsory+Licensing+Regime+and+the+Doha+Paragraph+6+System.&amp;rft.volume=37&amp;rft.pages=782-795&amp;rft.date=2015&amp;rft.aulast=Owoeye&amp;rft.aufirst=Olasupo&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-23\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">AFP Report (March 23, 2001). <a rel=\"nofollow\" class=\"external text\" href=\"http://sg.news.yahoo.com/010323/1/kz9m.html\">\"Price cuts have little impact on access to AIDS drugs in Uganda\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-02-28</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Price+cuts+have+little+impact+on+access+to+AIDS+drugs+in+Uganda&amp;rft.date=2001-03-23&amp;rft.au=AFP+Report&amp;rft_id=http%3A%2F%2Fsg.news.yahoo.com%2F010323%2F1%2Fkz9m.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-24\">^</a></b></span> <span class=\"reference-text\">Chequer, P., Sudo, E.C., &amp; Vitfria, M.A.A. (2000). The impact of anti-retroviral therapy in Brazil. Paper presented at International AIDS Conference in Durban, paper no. MoPpE1066.</span>\n</li>\n<li id=\"cite_note-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-25\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Norviel, Vern; Hoffmeister, David M. (September 30, 2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.law360.com/articles/709116/a-look-at-the-legality-behind-daraprim-s-price-spike\">\"A Look At The Legality Behind Daraprim's Price Spike -\"</a>. <i>www.law360.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.law360.com&amp;rft.atitle=A+Look+At+The+Legality+Behind+Daraprim%27s+Price+Spike+-&amp;rft.date=2015-09-30&amp;rft.aulast=Norviel&amp;rft.aufirst=Vern&amp;rft.au=Hoffmeister%2C+David+M.&amp;rft_id=https%3A%2F%2Fwww.law360.com%2Farticles%2F709116%2Fa-look-at-the-legality-behind-daraprim-s-price-spike&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-26\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Muoio, Dave (September 17, 2015). <a rel=\"nofollow\" class=\"external text\" href=\"https://www.healio.com/infectious-disease/hiv-aids/news/online/%7B745d9cc5-df37-4139-b1ac-6dde7b8ae463%7D/daraprim-price-jump-raises-concerns-among-id-groups-providers\">\"Daraprim price jump raises concerns among ID groups, providers\"</a>. <i>www.healio.com</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.healio.com&amp;rft.atitle=Daraprim+price+jump+raises+concerns+among+ID+groups%2C+providers&amp;rft.date=2015-09-17&amp;rft.aulast=Muoio&amp;rft.aufirst=Dave&amp;rft_id=https%3A%2F%2Fwww.healio.com%2Finfectious-disease%2Fhiv-aids%2Fnews%2Fonline%2F%257B745d9cc5-df37-4139-b1ac-6dde7b8ae463%257D%2Fdaraprim-price-jump-raises-concerns-among-id-groups-providers&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-27\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-27\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">Schlanger, Zo\u00eb (2015-09-21). <a rel=\"nofollow\" class=\"external text\" href=\"http://www.newsweek.com/martin-shkreli-daraprim-drug-prices-374922\">\"Martin Shkreli on Raising Price of AIDS Drug 5,000 Percent: 'I Think Profits Are a Great Thing<span style=\"padding-right:0.2em;\">'</span>\"</a>. <i>Newsweek</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-07</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Newsweek&amp;rft.atitle=Martin+Shkreli+on+Raising+Price+of+AIDS+Drug+5%2C000+Percent%3A+%27I+Think+Profits+Are+a+Great+Thing%27&amp;rft.date=2015-09-21&amp;rft.aulast=Schlanger&amp;rft.aufirst=Zo%C3%AB&amp;rft_id=http%3A%2F%2Fwww.newsweek.com%2Fmartin-shkreli-daraprim-drug-prices-374922&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-28\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-28\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Directorate, Government of Canada, Health Canada, Health Products and Food Branch, Therapeutic Products. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.camr-rcam.gc.ca/index-eng.php\">\"Canada's Access to Medicines Regime\"</a>. <i>www.camr-rcam.gc.ca</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 February</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.camr-rcam.gc.ca&amp;rft.atitle=Canada%27s+Access+to+Medicines+Regime&amp;rft.aulast=Directorate&amp;rft.aufirst=Government+of+Canada%2C+Health+Canada%2C+Health+Products+and+Food+Branch%2C+Therapeutic+Products&amp;rft_id=http%3A%2F%2Fwww.camr-rcam.gc.ca%2Findex-eng.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-29\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-29\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\">Directorate, Government of Canada, Health Canada, Health Products and Food Branch, Therapeutic Products. <a rel=\"nofollow\" class=\"external text\" href=\"http://www.camr-rcam.gc.ca/intro/index-eng.php\">\"Introduction - Canada's Access to Medicines Regime\"</a>. <i>www.camr-rcam.gc.ca</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 February</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.camr-rcam.gc.ca&amp;rft.atitle=Introduction+-+Canada%27s+Access+to+Medicines+Regime&amp;rft.aulast=Directorate&amp;rft.aufirst=Government+of+Canada%2C+Health+Canada%2C+Health+Products+and+Food+Branch%2C+Therapeutic+Products&amp;rft_id=http%3A%2F%2Fwww.camr-rcam.gc.ca%2Fintro%2Findex-eng.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-30\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-30\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.msfaccess.org/the-access-campaign\">\"About Us\"</a><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">10 February</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=About+Us&amp;rft_id=https%3A%2F%2Fwww.msfaccess.org%2Fthe-access-campaign&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-31\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-31\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Mbwasi, Romuald; Mlaki, Wilson. <a rel=\"nofollow\" class=\"external text\" href=\"https://doi.org/10.1016/S0140-6736(08)61070-3\">\"Increasing access to medicines in Tanzania\"</a>. <i>The Lancet</i>. <b>372</b> (9634): 205\u2013206. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1016/s0140-6736%2808%2961070-3\">10.1016/s0140-6736(08)61070-3</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Lancet&amp;rft.atitle=Increasing+access+to+medicines+in+Tanzania&amp;rft.volume=372&amp;rft.issue=9634&amp;rft.pages=205-206&amp;rft_id=info%3Adoi%2F10.1016%2Fs0140-6736%2808%2961070-3&amp;rft.aulast=Mbwasi&amp;rft.aufirst=Romuald&amp;rft.au=Mlaki%2C+Wilson&amp;rft_id=https%3A%2F%2Fdoi.org%2F10.1016%2FS0140-6736%2808%2961070-3&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-32\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-32\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.gavi.org/about/mission/\">\"Gavi's mission\"</a>. <i>www.gavi.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-15</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.gavi.org&amp;rft.atitle=Gavi%27s+mission&amp;rft_id=http%3A%2F%2Fwww.gavi.org%2Fabout%2Fmission%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-33\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-33\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.gavi.org/about/gavis-partnership-model/\">\"Gavi's partnership model\"</a>. <i>www.gavi.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-15</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.gavi.org&amp;rft.atitle=Gavi%27s+partnership+model&amp;rft_id=http%3A%2F%2Fwww.gavi.org%2Fabout%2Fgavis-partnership-model%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-:7-34\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:7_34-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:7_34-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation book\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.worldcat.org/oclc/881325330\"><i>Law and global health</i></a>. Freeman, Michael D. A.,, Hawkes, Sarah,, Bennett, Belinda,. Oxford. <a href=\"/wiki/International_Standard_Book_Number\" title=\"International Standard Book Number\">ISBN</a>&#160;<a href=\"/wiki/Special:BookSources/9780199688999\" title=\"Special:BookSources/9780199688999\">9780199688999</a>. <a href=\"/wiki/OCLC\" title=\"OCLC\">OCLC</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/oclc/881325330\">881325330</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Law+and+global+health&amp;rft.place=Oxford&amp;rft_id=info%3Aoclcnum%2F881325330&amp;rft.isbn=9780199688999&amp;rft_id=https%3A%2F%2Fwww.worldcat.org%2Foclc%2F881325330&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-35\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-35\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.wto.org/english/res_e/booksp_e/casestudies_e/case19_e.htm\">\"WTO | Managing the Challenges of WTO Participation: Case Study\"</a>. <i>www.wto.org</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2018-03-15</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.wto.org&amp;rft.atitle=WTO+%7C+Managing+the+Challenges+of+WTO+Participation%3A+Case+Study&amp;rft_id=https%3A%2F%2Fwww.wto.org%2Fenglish%2Fres_e%2Fbooksp_e%2Fcasestudies_e%2Fcase19_e.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-36\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-36\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation news\">\"Lobby Petitions Government, Pharmaceutical Companies\". <i>Africa News Service</i>. September 23, 2003.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Africa+News+Service&amp;rft.atitle=Lobby+Petitions+Government%2C+Pharmaceutical+Companies&amp;rft.date=2003-09-23&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAccess+to+medicines\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw1330\nCached time: 20180903052807\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.324 seconds\nReal time usage: 0.353 seconds\nPreprocessor visited node count: 1643/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 54932/2097152 bytes\nTemplate argument size: 83/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 42648/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.151/10.000 seconds\nLua memory usage: 3.03 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  238.111      1 Template:Reflist\n100.00%  238.111      1 -total\n 44.59%  106.184     16 Template:Cite_web\n 27.32%   65.057     14 Template:Cite_journal\n  7.46%   17.769      4 Template:Cite_news\n  2.24%    5.341      1 Template:Cite_book\n  0.95%    2.264      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:53143403-0!canonical and timestamp 20180903052807 and revision id 851144623\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","*":"World_Health_Organization"}],"links":[{"ns":0,"exists":"","*":"AIDS epidemic"},{"ns":0,"exists":"","*":"AIDS medication"},{"ns":0,"exists":"","*":"Access to Medicine Index"},{"ns":0,"exists":"","*":"Africa"},{"ns":0,"exists":"","*":"Antimalarial medication"},{"ns":0,"exists":"","*":"Antiparasitic"},{"ns":0,"exists":"","*":"Antiretroviral"},{"ns":0,"exists":"","*":"Belize"},{"ns":0,"exists":"","*":"Bill & Melinda Gates Foundation"},{"ns":0,"exists":"","*":"Brazil"},{"ns":0,"exists":"","*":"Campaign for Access to Essential Medicines"},{"ns":0,"exists":"","*":"Canada's Access to Medicines Regime"},{"ns":0,"exists":"","*":"Cancer"},{"ns":0,"exists":"","*":"Cervical cancer"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Compulsory license"},{"ns":0,"exists":"","*":"Daraprim"},{"ns":0,"exists":"","*":"Data exclusivity"},{"ns":0,"exists":"","*":"Developing country"},{"ns":0,"exists":"","*":"Developing world"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Dispute resolution"},{"ns":0,"exists":"","*":"Doha Declaration"},{"ns":0,"exists":"","*":"Enforcement"},{"ns":0,"exists":"","*":"Essential medicines"},{"ns":0,"exists":"","*":"Exclusive right"},{"ns":0,"exists":"","*":"Free markets"},{"ns":0,"exists":"","*":"Gavi, the Vaccine Alliance"},{"ns":0,"exists":"","*":"Generic brand"},{"ns":0,"exists":"","*":"Generic drug"},{"ns":0,"exists":"","*":"Guatemala"},{"ns":0,"exists":"","*":"HIV/AIDS"},{"ns":0,"exists":"","*":"HIV/AIDS treatment"},{"ns":0,"exists":"","*":"Haemophilus influenzae"},{"ns":0,"exists":"","*":"Health"},{"ns":0,"exists":"","*":"Hepatitis B"},{"ns":0,"exists":"","*":"Hepatitis B vaccine"},{"ns":0,"exists":"","*":"Hepatitis C"},{"ns":0,"exists":"","*":"Hib vaccine"},{"ns":0,"exists":"","*":"Honduras"},{"ns":0,"exists":"","*":"Human papillomavirus infection"},{"ns":0,"exists":"","*":"India"},{"ns":0,"exists":"","*":"Infrastructure"},{"ns":0,"exists":"","*":"Intellectual Property Rights"},{"ns":0,"exists":"","*":"Intellectual property"},{"ns":0,"exists":"","*":"Intellectual property laws"},{"ns":0,"exists":"","*":"International Standard Book Number"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"International aid"},{"ns":0,"exists":"","*":"International law"},{"ns":0,"exists":"","*":"International trading system"},{"ns":0,"exists":"","*":"Kenya"},{"ns":0,"exists":"","*":"Latin America"},{"ns":0,"exists":"","*":"Malaria"},{"ns":0,"exists":"","*":"Malawi"},{"ns":0,"exists":"","*":"Market competition"},{"ns":0,"exists":"","*":"Martin Shkreli"},{"ns":0,"exists":"","*":"Medication"},{"ns":0,"exists":"","*":"Medicines"},{"ns":0,"exists":"","*":"Monopoly"},{"ns":0,"exists":"","*":"M\u00e9decins Sans Fronti\u00e8res"},{"ns":0,"exists":"","*":"OCLC"},{"ns":0,"exists":"","*":"Patent"},{"ns":0,"exists":"","*":"Patent laws"},{"ns":0,"exists":"","*":"Patent protection"},{"ns":0,"exists":"","*":"Pharmaceutical companies"},{"ns":0,"exists":"","*":"Pharmaceutical drugs"},{"ns":0,"exists":"","*":"Price gouging"},{"ns":0,"exists":"","*":"Public health"},{"ns":0,"exists":"","*":"Public\u2013private partnership"},{"ns":0,"exists":"","*":"Pyrimethamine"},{"ns":0,"exists":"","*":"Research and development"},{"ns":0,"exists":"","*":"Right to health"},{"ns":0,"exists":"","*":"South Africa"},{"ns":0,"exists":"","*":"Southeast Asia"},{"ns":0,"exists":"","*":"Streptococcus pneumoniae"},{"ns":0,"exists":"","*":"TRIPS Agreement"},{"ns":0,"exists":"","*":"Tanzania"},{"ns":0,"exists":"","*":"Toxoplasmosis"},{"ns":0,"exists":"","*":"Tuberculosis"},{"ns":0,"exists":"","*":"Turing Pharmaceuticals"},{"ns":0,"exists":"","*":"UNAIDS"},{"ns":0,"exists":"","*":"UNICEF"},{"ns":0,"exists":"","*":"Uganda"},{"ns":0,"exists":"","*":"Vaccine"},{"ns":0,"exists":"","*":"Vaccine-preventable diseases"},{"ns":0,"exists":"","*":"WHO Model List of Essential Medicines"},{"ns":0,"exists":"","*":"WTO Ministerial Conference of 2001"},{"ns":0,"exists":"","*":"World Bank"},{"ns":0,"exists":"","*":"World Health Organization"},{"ns":0,"exists":"","*":"World Trade Organization"}],"templates":[{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite news"},{"ns":10,"exists":"","*":"Template:Cite book"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Martin_Shkreli_House_Committee_on_Oversight_and_Government_Reform_2016.jpg","World_Trade_Organization_(logo_and_wordmark).svg","AIDS_and_HIV_prevalence_2009.svg","5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine_200.svg"],"externallinks":["http://www.who.int/mediacentre/news/statements/2009/access-medicines-20090313/en/","http://www.who.int/medicines/areas/human_rights/en/","http://www.unsgaccessmeds.org/final-report","//doi.org/10.1056/NEJMp1613861","http://journalofethics.ama-assn.org/2006/12/hlaw1-0612.html","//doi.org/10.1001/virtualmentor.2006.8.12.hlaw1-0612","https://www.forbes.com/sites/robertpearl/2017/01/19/why-patent-protection-in-the-drug-industry-is-out-of-control/#97d25fa78ca9","https://dx.doi.org.ezproxy.neu.edu/10.3389/fmed.2017.00218","//doi.org/10.3389/fmed.2017.00218","http://linkinghub.elsevier.com/retrieve/pii/S0140673610620429","//doi.org/10.1016/s0140-6736(10)62042-9","https://dx.doi.org.ezproxy.neu.edu/10.2105/AJPH.2014.302236","//doi.org/10.2105/ajph.2014.302236","http://onlinelibrary.wiley.com/doi/10.1111/jore.12171/abstract","//doi.org/10.1111/jore.12171","//www.worldcat.org/issn/1467-9795","https://link.springer.com/article/10.1007/s12116-015-9184-4","//doi.org/10.1007/s12116-015-9184-4","//www.worldcat.org/issn/0039-3606","https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm","http://www.who.int/medicines/areas/policy/wto_trips/en/","http://onlinelibrary.wiley.com/doi/10.1038/sj.clpt.6100359/abstract","//doi.org/10.1038/sj.clpt.6100359","//www.worldcat.org/issn/1532-6535","http://www.who.int/medicines/areas/policy/doha_declaration/en/","https://www.wto.org/english/thewto_e/glossary_e/paragraph6_e.htm","http://doi.wiley.com/10.1111/jwip.12083","//doi.org/10.1111/jwip.12083","//www.worldcat.org/issn/1422-2213","http://sg.news.yahoo.com/010323/1/kz9m.html","https://www.law360.com/articles/709116/a-look-at-the-legality-behind-daraprim-s-price-spike","https://www.healio.com/infectious-disease/hiv-aids/news/online/%7B745d9cc5-df37-4139-b1ac-6dde7b8ae463%7D/daraprim-price-jump-raises-concerns-among-id-groups-providers","http://www.newsweek.com/martin-shkreli-daraprim-drug-prices-374922","http://www.camr-rcam.gc.ca/index-eng.php","http://www.camr-rcam.gc.ca/intro/index-eng.php","https://www.msfaccess.org/the-access-campaign","https://doi.org/10.1016/S0140-6736(08)61070-3","//doi.org/10.1016/s0140-6736(08)61070-3","http://www.gavi.org/about/mission/","http://www.gavi.org/about/gavis-partnership-model/","https://www.worldcat.org/oclc/881325330","//www.worldcat.org/oclc/881325330","https://www.wto.org/english/res_e/booksp_e/casestudies_e/case19_e.htm"],"sections":[{"toclevel":1,"level":"2","line":"Hindrances to access","number":"1","index":"1","fromtitle":"Access_to_medicines","byteoffset":1361,"anchor":"Hindrances_to_access"},{"toclevel":2,"level":"3","line":"Patent protection and exclusivity","number":"1.1","index":"2","fromtitle":"Access_to_medicines","byteoffset":1468,"anchor":"Patent_protection_and_exclusivity"},{"toclevel":2,"level":"3","line":"Data exclusivity","number":"1.2","index":"3","fromtitle":"Access_to_medicines","byteoffset":2799,"anchor":"Data_exclusivity"},{"toclevel":2,"level":"3","line":"Cost","number":"1.3","index":"4","fromtitle":"Access_to_medicines","byteoffset":3967,"anchor":"Cost"},{"toclevel":2,"level":"3","line":"Lack of Generic Brands","number":"1.4","index":"5","fromtitle":"Access_to_medicines","byteoffset":6644,"anchor":"Lack_of_Generic_Brands"},{"toclevel":1,"level":"2","line":"Legislation","number":"2","index":"6","fromtitle":"Access_to_medicines","byteoffset":8301,"anchor":"Legislation"},{"toclevel":2,"level":"3","line":"Trips agreement","number":"2.1","index":"7","fromtitle":"Access_to_medicines","byteoffset":8526,"anchor":"Trips_agreement"},{"toclevel":2,"level":"3","line":"Doha Declaration","number":"2.2","index":"8","fromtitle":"Access_to_medicines","byteoffset":10686,"anchor":"Doha_Declaration"},{"toclevel":3,"level":"4","line":"Paragraph 6 System","number":"2.2.1","index":"9","fromtitle":"Access_to_medicines","byteoffset":12466,"anchor":"Paragraph_6_System"},{"toclevel":1,"level":"2","line":"Differences by geography","number":"3","index":"10","fromtitle":"Access_to_medicines","byteoffset":13987,"anchor":"Differences_by_geography"},{"toclevel":2,"level":"3","line":"Africa","number":"3.1","index":"11","fromtitle":"Access_to_medicines","byteoffset":14215,"anchor":"Africa"},{"toclevel":2,"level":"3","line":"Latin America","number":"3.2","index":"12","fromtitle":"Access_to_medicines","byteoffset":14954,"anchor":"Latin_America"},{"toclevel":2,"level":"3","line":"India","number":"3.3","index":"13","fromtitle":"Access_to_medicines","byteoffset":15696,"anchor":"India"},{"toclevel":1,"level":"2","line":"Differences by sector","number":"4","index":"14","fromtitle":"Access_to_medicines","byteoffset":16532,"anchor":"Differences_by_sector"},{"toclevel":2,"level":"3","line":"Vaccines","number":"4.1","index":"15","fromtitle":"Access_to_medicines","byteoffset":16561,"anchor":"Vaccines"},{"toclevel":1,"level":"2","line":"Epidemics and access","number":"5","index":"16","fromtitle":"Access_to_medicines","byteoffset":17363,"anchor":"Epidemics_and_access"},{"toclevel":2,"level":"3","line":"HIV/AIDs","number":"5.1","index":"17","fromtitle":"Access_to_medicines","byteoffset":17390,"anchor":"HIV/AIDs"},{"toclevel":3,"level":"4","line":"Daraprim","number":"5.1.1","index":"18","fromtitle":"Access_to_medicines","byteoffset":17813,"anchor":"Daraprim"},{"toclevel":1,"level":"2","line":"Campaigns","number":"6","index":"19","fromtitle":"Access_to_medicines","byteoffset":19791,"anchor":"Campaigns"},{"toclevel":1,"level":"2","line":"See also","number":"7","index":"20","fromtitle":"Access_to_medicines","byteoffset":24325,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"8","index":"21","fromtitle":"Access_to_medicines","byteoffset":24412,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Access to medicines","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q29468924"}]}}